U.S. Stock Futures Rise Ahead of Holiday-Shortened Week as AI Optimism Lifts Tech 
IMF Reaches Staff-Level Agreement With Egypt, Opening Path to $3.8 Billion in Funding 
US and Japan Fast-Track $550 Billion Strategic Investment Initiative 
Gold Price Breaks $4,500 as Safe-Haven Demand and Rate Cut Bets Fuel Rally 
China Keeps Benchmark Lending Rates Steady as Economic Outlook Remains Cautious 
Global Demand for Yuan Loans and Bonds Surges as China Pushes Currency Internationalization 
Oil Prices Edge Higher as Strong U.S. Growth and Supply Risks Support Market 
RBA Signals Possible Interest Rate Hike in 2026 as Inflation Pressures Persist 
BOJ Minutes Reveal Growing Debate Over Interest Rate Hikes and Inflation Risks 
Japan Signals Possible Yen Intervention as Currency Weakens Despite BOJ Rate Hike 
UK Economy Grows 0.1% in Q3 2025 as Outlook Remains Fragile 
Asian Markets Rise as AI Rally Caps 2025, Gold and Silver Hit Record Highs 
Global Markets Rise as Tech Stocks Lead, Yen Strengthens, and Commodities Hit Record Highs 
U.S. Dollar Slips as Yen Finds Support on Intervention Signals and Geopolitical Risks Rise 
Yen Slides as BOJ Caution Undercuts Rate Hike Impact 
South Korea Central Bank Warns of Rising Financial Stability Risks Amid Won Volatility 
Eli Lilly to Introduce Mounjaro Weight-Loss Drug in Hong Kong by Year-End
Global pharmaceutical giant Eli Lilly is gearing up to launch its weight-loss drug, Mounjaro, in Hong Kong by the end of this year. According to a report from Bloomberg News, the company has received approval from Hong Kong's government to sell its tirzepatide injections under the Mounjaro brand.
Mounjaro for Weight Management and Diabetes
Eli Lilly's Mounjaro is designed for both long-term weight management and the treatment of type 2 diabetes. It will be available on the Kwikpen device, which allows for easy self-administration. The company aims to address the growing demand for effective weight-loss treatments while continuing to provide solutions for diabetes management.
Hong Kong Market Entry
Hong Kong marks a strategic entry point for Eli Lilly as it expands its global presence. With the approval of Mounjaro, the company is poised to offer a highly anticipated solution for individuals struggling with obesity and related health issues. The weight-loss sector has seen significant growth in recent years, and Mounjaro is expected to make a notable impact.
